Sun Pharma's diabetes NCE show promise; to go into phase 1 trials in Q3

Sun Pharma's new molecule for diabetes treatment is likely to get into phase 1 clinical trials in the third quarter of this fiscal after it showed promise in animal trials, the company said on Wednesday.

The stock prices, however, dropped by 3.3 per cent on the BSE at the end of day's trade.

The new chemical entity (NCE) named GL0034 is a long acting molecule used to treat patients with type 2 diabetes. These are called long acting GLP -1R agonists.

Dilip Shanghvi, Managing Director, Sun Pharma said, “We are excited by the robust pre-clinical data for GL0034 and believe